Table 1.
Patient characteristics and clinical results
| Tumor response† | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient No. | Age (years) | Sex | Diagnosis | Previous treatments | Relapse site status at time of vaccination | Vaccines given* | Toxicity | 8w | 18w |
| 1 | 15.5 | M | Anaplastic Astrocytoma | S, R, C: CCNU TEMOZ | Nodules in resection margin | 5 | none | SD | SD |
| 2# | 22 | F | Medulloblastoma | S, R, C: VCR, ETO, CISP, MEL H, CYC H + PBSC, oETO, CCNU | NA | 0 | NA | NA | NA |
| 3# | 14 | F | Pilocytic Astrocytoma | S, R, C: CARB 6TG, PROC, CCNU, VCR | NA | 0 | NA | NA | NA |
| 4 | 16.5 | F | Glioblastoma Multiforme | S, R | NMD | 3 | none | PD | PD |
| 5 | 13.5 | F | Glioblastoma Multiforme | S, R, C: CCNU, VCR | Nodules in resection margin | 3 | none | PD | PD |
| 6 | 9 | F | Ependymoma | S, R, C: CISP, CYC, VCR, oETO | NMD | 3 | none | SD | PD |
| 7 | 19.5 | F | Ependymoma (spinal) | S, R, C: CYC H, CARB CISP, IRINO | Multiple metastatic nodules | 3 | none | SD | NA |
| 8 | 13 | F | Pleomorphic Xanthoastrocytoma | S, R, C: CCNU, TEMOZ | Nodules in resection margin | 4 | none | PR | SD |
| 9 | 16 | F | Ependymoma | S, R | NMD | 3 | none | SD | NA |
Abbreviations: C, chemotherapy; CARB, carboplatin; CISP, cisplatin; CYC, cyclophosphamide; CYC H, cyclophosphamide high-dose therapy; DOX, doxorubicin; ETO, etoposide; 5FU, 5-fluorouracil; IFO, ifosfamide; IRINO, irinotecan; MEL H, melphalan high-dose therapy; NA, not applicable; NMD, no measurable disease; oETO, oral etoposide; +PBSC, peripheral blood stem cell (autologous stem cell support); PD, progressive disease; PR, partial response; PROC, procarbazine; R, radiation; S, surgery; SD, stable disease; TEMOZ temozolamide, 6TG 6-thioguanine, VCR, vincristine.
Patients 2 and 3 did not complete study protocol, and evaluations are incomplete.
One DCRNA vaccine includes both intradermal and intravenous components.
Tumor response at 8 and 18 weeks from first DCRNA vaccine.